{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:34:39Z","timestamp":1773772479088,"version":"3.50.1"},"reference-count":46,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1134\/s1607672924700856","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T05:03:28Z","timestamp":1718082208000},"page":"156-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis"],"prefix":"10.1134","volume":"517","author":[{"given":"L. A.","family":"Garzanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. P.","family":"Ananyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Koneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. V.","family":"Desinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Starovoytova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. B.","family":"Ovsyannikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. U.","family":"Shayakhmetova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. I.","family":"Glukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"7531_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0140-6736(17)30933-9","volume":"390","author":"Ch.P. Denton","year":"2017","unstructured":"Denton, Ch.P. and Khanna, D., Systemic sclerosis, Lancet, 2017, vol. 390, no. 10103, pp. 1685\u20131699. https:\/\/doi.org\/10.1016\/s0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"7531_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.rdc.2015.04.002","volume":"41","author":"E.P. Stern","year":"2015","unstructured":"Stern, E.P. and Denton, Ch.P., The pathogenesis of systemic sclerosis, Rheum. Dis. Clin. North Am., 2015, vol. 41, no. 3, pp. 367\u2013382. https:\/\/doi.org\/10.1016\/j.rdc.2015.04.002","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"7531_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M. Brown","year":"2019","unstructured":"Brown, M. and O\u2019Reilly, S., The immunopathogenesis of fibrosis in systemic sclerosis, Clin. Exp. Immunol., 2019, vol. 195, no. 3, pp. 310\u2013321. https:\/\/doi.org\/10.1111\/cei.13238","journal-title":"Clin. Exp. Immunol."},{"key":"7531_CR4","doi-asserted-by":"publisher","first-page":"933468","DOI":"10.3389\/fimmu.2022.933468","volume":"12","author":"B. Thoreau","year":"2022","unstructured":"Thoreau, B., Chaigne, B., and Mouthon, L., Role of B-cell in the pathogenesis of systemic sclerosis, Front. Immunol., 2022, vol. 12, no. 13, p. 933468. https:\/\/doi.org\/10.3389\/fimmu.2022.933468","journal-title":"Front. Immunol."},{"key":"7531_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.47360\/1995-4484-2020-520-531","volume":"58","author":"L.P. Ananieva","year":"2020","unstructured":"Ananieva, L.P., Current therapy of interstitial pneumonia associated with systemic scleroderma, Nauchno-Prakt. \n               Revmatol., 2020, vol. 58, no. 5, pp. 520\u2013531. https:\/\/doi.org\/10.47360\/1995-4484-2020-520-531","journal-title":"Revmatol."},{"key":"7531_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/1346-8138.13184","volume":"43","author":"A. Yoshizaki","year":"2016","unstructured":"Yoshizaki, A., B lymphocytes in systemic sclerosis: abnormalities and therapeutic targets, J. Dermatol., 2016, vol. 43, no. 1, pp. 39\u201345. https:\/\/doi.org\/10.1111\/1346-8138.13184","journal-title":"J. Dermatol."},{"key":"7531_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","volume":"38","author":"S. Sanges","year":"2017","unstructured":"Sanges, S., Guerrier, T., Launay, D., Lef\u00e8vre, G., Labalette, M., Forestier, A., Sobanski, V., Corli, J., Hauspie, C., Jendoubi, M., Yakoub-Agha, I., Hatron, P.-Y., Hachulla, E., and Dubucquoi, S., Role of B cells in the pathogenesis of systemic sclerosis, Rev. Med. Interne, 2017, vol. 38, no. 2, pp. 113\u2013124. https:\/\/doi.org\/10.1016\/j.revmed.2016.02.016","journal-title":"Rev. Med. Interne"},{"key":"7531_CR8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S. Jordan","year":"2015","unstructured":"Jordan, S., Distler, J.H.W., Maurer, B., Huscher, D., Van Laar, J.M., Allanore, Ya., and Distler, O., Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group, Ann. Rheumatic Dis., 2015, vol. 74, no. 6, pp. 1188\u20131194. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204522","journal-title":"Ann. Rheumatic Dis."},{"key":"7531_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D. Daoussis","year":"2017","unstructured":"Daoussis, D., Melissaropoulos, K., Sakellaropoulos, G., Antonopoulos, I., Markatseli, T.E., Simopoulou, T., Georgiou, P., Andonopoulos, A.P., Drosos, A.A., Sakkas, L., and Liossis, S.-N., A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease, Semin. Arthritis Rheum., 2017, vol. 46, no.\u00a05, pp. 625\u2013631. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin. Arthritis Rheum."},{"key":"7531_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M. Thiebaut","year":"2018","unstructured":"Thiebaut, M., Launay, D., Rivi\u00e8re, S., Mah\u00e9vas, T., Bellakhal, S., Hachulla, E., Fain, O., and Mekinian, A., Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review, Autoimmun. Rev., 2018, vol. 17, no. 6, pp. 582\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","journal-title":"Autoimmun. Rev."},{"key":"7531_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M. Elhai","year":"2019","unstructured":"Elhai, M., Boubaya, M., Distler, O., Smith, V., Matucci-Cerinic, M., Alegre Sancho, J.J., Truchetet, M.-E., Braun-Moscovici, Yo., Iannone, F., Novikov, P.I., Lescoat, A., Siegert, E., Castellv\u00ed, I., Air\u00f3, P., Vettori, S., De Langhe, E., Hachulla, E., Erler, A., Ananieva, L., Krusche, M., L\u00f3pez-Longo, F.J., Distler, J.H.W., Hunzelmann, N., Hoffmann-Vold, A.-M., Riccieri, V., Hsu, V.M., Pozzi, M.R., Ancuta, C., Rosato, E., Mihai, C., Kuwana, M., Saketkoo, L.A., Chizzolini, C., Hesselstrand, R., Ullman, S., Yavuz, S., Rednic, S., Caimmi, C., Bloch-Queyrat, C., and Allanore, Ya., Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study, Ann. Rheum. Dis., 2019, vol. 78, no. 7, pp.\u00a0979\u2013987. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816","journal-title":"Ann. Rheum. Dis."},{"key":"7531_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.47360\/1995-4484-2022-57-63","volume":"60","author":"L.P. Ananyeva","year":"2022","unstructured":"Ananyeva, L.P., Garzanova, L.A., Koneva, O.A., Starovoytova, M.N., Desinova, O.V., Ovsyannikova, O.B., Shayakhmetova, R.U., Cherkasova, M.V., Aleksankin, A.P., and Nasonov, E.L., Anti-topoisomerase 1 antibody level changes after B cell depletion therapy in systemic sclerosis, Nauchno-Prakt. \n               Revmatol., 2022, vol. 60, no. 1, pp. 57\u201363. https:\/\/doi.org\/10.47360\/1995-4484-2022-57-63","journal-title":"Revmatol."},{"key":"7531_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.14412\/1995-4484-2019-265-273","volume":"57","author":"L.P. Ananyeva","year":"2019","unstructured":"Ananyeva, L.P., Koneva, O.A., Desinova, O.V., Garzanova, L.A., Glukhova, S.I., Starovoitova, M.N., Ovsyannikova, O.B., Volkov, A.V., Aleksankin, A.P., and Nasonov, E.L., Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation, Nauchno-Prakt. \n               Revmatol., 2019, vol. 57, no. 3, pp.\u00a0265\u2013273. https:\/\/doi.org\/10.14412\/1995-4484-2019-265-273","journal-title":"Revmatol."},{"key":"7531_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.14412\/1995-4484-2013-1542","volume":"51","author":"L.P. Ananieva","year":"2013","unstructured":"Ananieva, L.P., Desinova, O.V., Koneva, O.A., Starovoitova, M.N., Yutkina, N.N., Volkov, A.V., Ovsyannikova, O.B., Aleksankin, A.P., Aleksandrova, E.N., Novikov, A.A., and Nasonov, E.L., Rituximab treatment for interstitial lung injury in scleroderma systematica, Nauchno-Prakt. \n               Revmatol., 2013, vol. 51, no. 5, pp. 514\u2013523. https:\/\/doi.org\/10.14412\/1995-4484-2013-1542","journal-title":"Revmatol."},{"key":"7531_CR15","volume-title":"Anti-B- kletochnaya terapiya v revmatologii: fokus na rituksimab (Anti-B-Cell Therapy in Rheumatology: Focus on Rituximab)","year":"2012","unstructured":"Anti-B- kletochnaya terapiya v revmatologii: fokus na rituksimab (Anti-B-Cell Therapy in Rheumatology: Focus on Rituximab), Nasonov, E.L., Ed., Moscow: IMA-PRESS, 2012."},{"key":"7531_CR16","doi-asserted-by":"publisher","unstructured":"Ebata, S., Yoshizaki-Ogawa, A., Sato, Sh., and Yoshizaki, A., New era in systemic sclerosis treatment: recently approved therapeutics, J. Clin. Med., 2022, vol.\u00a08, no. 11 (15), p. 4631. https:\/\/doi.org\/10.3390\/jcm11154631","DOI":"10.3390\/jcm11154631"},{"key":"7531_CR17","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A. Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina, A., Walker, K.M., Pope, J.E., and Group, S.A., Treatment algorithms for systemic sclerosis according to experts, Arthritis Rheumatol., 2018, vol.\u00a070, no. 11, pp. 1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol."},{"key":"7531_CR18","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R. Tang","year":"2020","unstructured":"Tang, R., Yu, J., Shi, Ya., Zou, P., Zeng, Zh., Tang, B., Wang, Ya., Ling, G., Luo, M., and Xiao, R., Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis, Int. Immunopharmacol., 2020, vol. 83, p. 106389. https:\/\/doi.org\/10.1016\/j.intimp.2020.106389","journal-title":"Int. Immunopharmacol."},{"key":"7531_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","volume":"61","author":"M.M.V. De Figueiredo Caldas","year":"2021","unstructured":"De Figueiredo Caldas, M.M.V., De Azevedo, K.P.M., De Fran\u00e7a Nunes, A.C., De Oliveira, V.H., Pimenta,\u00a0I.D.S.F., De Ara\u00fajo, I.D.T., Neto, F.A.B., Da Silveira Gon\u00e7alves De Oliveira, A.K., and Piuvezam, G., Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis, Adv. Rheumatology, 2021, vol.\u00a061, no. 1, p. 15. https:\/\/doi.org\/10.1186\/s42358-021-00170-y","journal-title":"Adv. Rheumatology"},{"key":"7531_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","volume":"60","author":"R.P. Goswami","year":"2021","unstructured":"Goswami, R.P., Ray, A., Chatterjee, M., Mukherjee, A., Sircar, G., and Ghosh, P., Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: a systematic review and meta-analysis, Rheumatology, 2021, vol. 60, no. 2, pp. 557\u2013567. https:\/\/doi.org\/10.1093\/rheumatology\/keaa550","journal-title":"Rheumatology"},{"key":"7531_CR21","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","volume":"6","author":"C. Kaegi","year":"2019","unstructured":"Kaegi, C., Wuest, B., Schreiner, J., Steiner, U.C., Vultaggio, A., Matucci, A., Crowley, C., and Boyman, O., Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders, Front. Immunol., 2019, vol. 6, no. 10, p. 1990. https:\/\/doi.org\/10.3389\/fimmu.2019.01990","journal-title":"Front. Immunol."},{"key":"7531_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.14412\/1995-4484-2014-495-506","volume":"52","author":"L.P. Ananieva","year":"2014","unstructured":"Ananieva, L.P., Soloviyov, S.K., Beketova, T.V., Vasiliev, V.I., Antelava, O.A., Aleksandrova, E.N., Koneva, O.A., Tsanyan, M.E., Desinova, O.V., Logvinenko, O.A., Volkov, A.V., Helkovskaya-Sergeeva, A.N., Novikov, A.A., Aleksankin, A.A., and Nasonov, Y.L., Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients, Nauchno-Prakt. \n               Revmatol., 2014, vol. 52, no. 5, pp.\u00a0495\u2013506. https:\/\/doi.org\/10.14412\/1995-4484-2014-495-506","journal-title":"Revmatol."},{"key":"7531_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14412\/1995-4484-2019-3-40","volume":"57","author":"E.L. Nasonov","year":"2019","unstructured":"Nasonov, E.L., Beketova, T.V., Ananyeva, L.P., Vasilyev, V.I., Solovyev, S.K., and Avdeeva, A.S., Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases, Nauchno-Prakt. \n               Revmatol., 2019, vol.\u00a057, pp. 1\u201340. https:\/\/doi.org\/10.14412\/1995-4484-2019-3-40","journal-title":"Revmatol."},{"key":"7531_CR24","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G. Sircar","year":"2018","unstructured":"Sircar, G., Goswami, R.P., Sircar, D., Ghosh, A., and Ghosh, P., Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial, Rheumatology (Oxford), 2018, vol. 57, no. 12, pp. 2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"key":"7531_CR25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.14412\/1995-4484-2016-510-519","volume":"54","author":"E.L. Nasonov","year":"2016","unstructured":"Nasonov, E.L., Zonova, E.V., Ivanova, O.N., Knyazeva, L.A., Mazurov, V.I., Samigullina, R.R., Marusenko, I.M., Nesmeyanova, O.B., Plaksina, T.V., Sizi-kov,\u00a0A.E., Krechikova, D.G., Petrochenkova, N.A., Shapovalova, Yu.S., Soroka, N.S., Pimanov, S.I., Pristrom, A.M., Kunder, E.V., Chernyaeva, E.V., Eremeeva, A.V., and Ivanov, R., The results of a phase III comparative clinical trial of rituximab (AcellbiaT and Sabthera\u00ae) in rheumatoid arthritis (The BIORA study), Nauchno-Prakt. \n               Revmatol., 2016, vol. 54, no. 5, pp.\u00a0510\u2013519. https:\/\/doi.org\/10.14412\/1995-4484-2016-510-519","journal-title":"Revmatol."},{"key":"7531_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3899\/jrheum.071401.c1","volume":"34","author":"T. Woodworth","year":"2007","unstructured":"Woodworth, T., Furst, D.E., Alten, R., Bingham, C.O.3., Yocum, D., and Sloan, V., Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0, J. Rheumatol., 2007, vol. 34, no. 6, pp.\u00a01401\u20131414. https:\/\/doi.org\/10.3899\/jrheum.071401.c1","journal-title":"J. Rheumatol."},{"key":"7531_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40264-019-00864-9","volume":"42","author":"Ch.M. Stach","year":"2019","unstructured":"Stach, Ch.M., Sloan, V.S., Woodworth, T.G., Kilgallen, B., and Furst, D.E., Rheumatology Common Toxicity Criteria (RCTC): an update reflecting real-world use, Drug Saf., 2019, vol. 42, no. 12, pp. 1499\u20131506. https:\/\/doi.org\/10.1007\/s40264-019-00864-9","journal-title":"Drug Saf."},{"key":"7531_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","volume":"74","author":"E.M. Vital","year":"2015","unstructured":"Vital, E.M., Dass, Sh., Buch, M.H., Rawstron, A.C., and Emery, P., An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial, Ann. Rheum. Dis., 2015, vol. 74, no. 6, pp.\u00a01195\u20131201. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204544","journal-title":"Ann. Rheum. Dis."},{"key":"7531_CR29","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s10067-021-05698-4","volume":"40","author":"M. Moradzadeh","year":"2021","unstructured":"Moradzadeh, M., Aghaei, M., Mehrbakhsh, Z., Arab-Bafrani, Z., and Abdollahi, N., Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis, Clin. Rheumatol., 2021, vol. 40, no. 10, pp. 3897\u20133918. https:\/\/doi.org\/10.1007\/s10067-021-05698-4","journal-title":"Clin. Rheumatol."},{"key":"7531_CR30","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.intimp.2021.107524","volume":"95","author":"N.-S. Xing","year":"2021","unstructured":"Xing, N.-S., Fan, G.-Z., Yan, F., Liu, Y.-P., and Zhang, R., Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis, Int. Immunopharmacol., 2021, vol. 95, p. 107524. https:\/\/doi.org\/10.1016\/j.intimp.2021.107524","journal-title":"Int. Immunopharmacol."},{"key":"7531_CR31","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1188\/10.cjon.e10-e21","volume":"14","author":"W.H. Vogel","year":"2010","unstructured":"Vogel, W.H., Infusion reactions: diagnosis, assessment, and management, Clin. J. Oncol. Nurs., 2010, vol. 14, no. 2, pp. e10\u2013e21. https:\/\/doi.org\/10.1188\/10.cjon.e10-e21","journal-title":"Clin. J. Oncol. Nurs."},{"key":"7531_CR32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","volume":"14","author":"D. Giuggioli","year":"2015","unstructured":"Giuggioli, D., Lumetti, F., Colaci, M., Fallahi, P., Antonelli, A., and Ferri, C., Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature, Autoimmun. Rev., 2015, vol. 14, no. 11, pp. 1072\u20131078. https:\/\/doi.org\/10.1016\/j.autrev.2015.07.008","journal-title":"Autoimmun. Rev."},{"key":"7531_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D. Daoussis","year":"2010","unstructured":"Daoussis, D., Liossis, S.-N.C., Tsamandas, A.C., Kalogeropoulou, Ch., Kazantzi, A., Sirinian, Ch., Karampetsou, M., Yiannopoulos, G., and Andonopoulos, A.P., Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study, Rheumatology, 2010, vol. 49, no. 2, pp. 271\u2013280. https:\/\/doi.org\/10.1093\/rheumatology\/kep093","journal-title":"Rheumatology"},{"key":"7531_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/rhu.0000000000000584","volume":"23","author":"A. Sari","year":"2017","unstructured":"Sari, A., Guven, D., Armagan, B., Erden, A., Kalyoncu, U., Karadag, O., Apras Bilgen, S., Ertenli, I., Kiraz, S., and Akdogan, A., Rituximab experience in patients with long-standing systemic sclerosis\u2013associated interstitial lung disease, J. Clin. Rheumatol., 2017, vol. 23, no. 8, pp. 411\u2013415. https:\/\/doi.org\/10.1097\/rhu.0000000000000584","journal-title":"J. Clin. Rheumatol."},{"key":"7531_CR35","unstructured":"Lepri, G., Avouac, J., Air\u00f2, P., Anguita Santos, F., Bellando Randone, S., Blagojevic, J., Distler, O., Garc\u00eca Hern\u00e0ndez, F.J., Gonzalez Nieto, J.A., Guiducci, S., Jordan, S., Limaye, V., Maurer, B., Riccieri, V., Selva-O\u2019calaghan, A., Matucci Cerinic, M., and Allanore, Y., Effects of rituximab in connective tissue disorders related interstitial lung disease, Clin. Exp. Rheumatol., 2016, vol. 34, no. suppl 100 5, pp. 181\u2013185."},{"key":"7531_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.41501","volume":"73","author":"R. Zonozi","year":"2021","unstructured":"Zonozi, R., Wallace, Z.S., Laliberte, K., Huizenga, N.R., Rosenthal, J.M., Rhee, E.P., Cortazar, F.B., and Niles,\u00a0J.L., Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease, Arthritis Rheumatol., 2021, vol. 73, no. 2, pp. 347\u2013354. https:\/\/doi.org\/10.1002\/art.41501","journal-title":"Arthritis Rheumatol."},{"key":"7531_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/acr.22281","volume":"66","author":"J.R. Curtis","year":"2014","unstructured":"Curtis, J.R., Yang, S., Patkar, N.M., Chen, L., Singh, J.A., Cannon, G.W., Mikuls, T.R., Delzell, E., Saag, K.G., Safford, M.M., Duvall, S., Alexander, K., Napalkov, P., Winthrop, K.L., Burton, M.J., Kamauu, A., and Baddley, J.W., Risk of hospitalized bacterial infections associated with biologic treatment among us veterans with rheumatoid arthritis, Arthritis Care Res. (Hoboken), 2014, vol. 66, no. 7, pp. 990\u2013997. https:\/\/doi.org\/10.1002\/acr.22281","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"7531_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"D.M. Roberts","year":"2015","unstructured":"Roberts, D.M., Jones, R.B., Smith, R.M., Alberici, F., Kumaratne, D.S., Burns, S., and Jayne, D.R.W., Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease, J. Autoimmun., 2015, vol.\u00a057, pp. 60\u201365. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009","journal-title":"J. Autoimmun."},{"key":"7531_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jcpt.12522","volume":"42","author":"K. Sharif","year":"2017","unstructured":"Sharif, K., Watad, A., Bragazzi, N.L., Asher, E., Abu Much, A., Horowitz, Y., Lidar, M., Shoenfeld, Y., and Amital, H., Anterior ST-elevation myocardial infarction induced by rituximab infusion: a case report and review of the literature, J. Clin. Pharm. Ther., 2017, vol.\u00a042, no. 3, pp. 356\u2013362. https:\/\/doi.org\/10.1111\/jcpt.12522","journal-title":"J. Clin. Pharm. Ther."},{"key":"7531_CR40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2019-eular.6816","volume":"78","author":"O. Koneva","year":"2019","unstructured":"Koneva, O., Ananyeva, L.P., Garzanova, L., Desinova, O., Ovsyannikova, O., and Starovoytova, M., Rituximab and cyclophosphamide comparison for efficacy and safety in the patients with systemic sclerosis associated with interstitial lung disease, Ann. Rheum. Dis., 2019, vol. 78, p. 169.","journal-title":"Ann. Rheum. Dis."},{"key":"7531_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.25039","volume":"62","author":"E.W. St Clair","year":"2010","unstructured":"St Clair, E.W., Good and bad memories following rituximab therapy, Arthritis Rheum., 2010, vol. 62, no. 1, pp. 1\u20135. https:\/\/doi.org\/10.1002\/art.25039","journal-title":"Arthritis Rheum."},{"key":"7531_CR42","volume-title":"Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidrogo artrita (Biological Drugs in the Treatment of Rheumatoid Arthritis)","year":"2013","unstructured":"Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidrogo artrita (Biological Drugs in the Treatment of Rheumatoid Arthritis), Nasonov, E.L., Ed., Moscow: IMA-PRESS, 2013."},{"key":"7531_CR43","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/nejmoa1404231","volume":"371","author":"L. Guillevin","year":"2014","unstructured":"Guillevin, L., Pagnoux, Ch., Karras, A., Khouatra, Ch., Auma\u00eetre, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., Qu\u00e9meneur, T., Blanchard-Delaunay, C., Godmer, P., Pu\u00e9chal, X., Carron, P.-L., Hatron, P.-Y., Limal, N., Hamidou, M., Ducret, M., Daugas, E., Papo, T., Bonnotte, B., Mahr, A., Ravaud, P., and Mouthon, L., Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis, New Engl. J. Med., 2014, vol. 371, pp. 1771\u20131780. https:\/\/doi.org\/10.1056\/nejmoa1404231","journal-title":"New Engl. J. Med."},{"key":"7531_CR44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878corr1","volume":"77","author":"P. Charles","year":"2018","unstructured":"Charles, P., Terrier, B., Perrodeau, E., Cohen, P., Faguer, S., Huart, A., et al., Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2, Ann. Rheum. Dis., 2018, vol. 77, pp.\u00a01143\u20131149. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878corr1","journal-title":"Ann. Rheum. Dis."},{"key":"7531_CR45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"B.H. Rovin","year":"2012","unstructured":"Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, et al., Group, L.U.N.A.R.I., Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study, Arthritis Rheum., 2012, vol. 64, no. 4, pp. 1215\u20131226. https:\/\/doi.org\/10.1002\/art.34359","journal-title":"Arthritis Rheum."},{"key":"7531_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"Ch.V. Oddis","year":"2013","unstructured":"Oddis, Ch.V., Reed, A.M., Aggarwal, R., Rider, L.G., Ascherman, D.P., Levesque, M.C., Barohn, R.J., Feldman, B.M., Harris-love, M.O., Koontz, D.C., Fertig, N., Kelley, S.S., Pryber, Sh.L., Miller, F.W., and Rockette, H.E., Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial, Arthritis Rheum., 2013, vol. 65, no. 2, pp. 314\u2013324. https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700856.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924700856","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700856.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:18:44Z","timestamp":1773760724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924700856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7531"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924700856","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of this work declare that they have no conflicts of interest. The authors are solely responsible for providing the final version of the manuscript. All authors took part in developing the concept of the article and writing the manuscript. The final version of the manuscript was approved by all authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}},{"value":"The study was approved by the local ethics committee of the Nasonova Research Institute of Rheumatology (protocol no. 10 dated June 3, 2021). All study participants signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}]}}